Treatment of Novel Coronavirus (2019-nCoV) Using Hinokitiol (β-thujaplicin) Copper Chelate

ABSTRACT

Human Coronavirus (HCoV) or Novel Coronavirus (2019-nCoV) is probably a brand new version of coronavirus that belongs to Betacoronaviruses kind Human Coronaviruses, similar to the Severe Acute Respiratory Syndrome (SARS) coronavirus and Middle-East Respiratory Syndrome (MERS) coronavirus. China recorded the number one case of this virus in December 2019 at Wuhan, the capital town of Hubei province. By 27 March 2020, 1000 CET, nearly 23,335 humans died out of 509,164 showed instances recorded throughout the world. By the give up of January 2020, China showed that the Novel Coronavirus (2019-nCoV) transmitted from one human to another. This studies pursuits to research a completely specific medicament called "Hinokitiol Copper Chelate” towards the large quantity 2019-nCoV Spike Glycoprotein with a unmarried receptor binding domain. This take a look at gives a super version for Hinokitiol Copper Chelate to be examined in silico towards 2019-nCoV Main Protease. © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2022.